Moreover, by analyzing the clinical characteristics of patients with glioma, we found that the risk score was positively correlated with malignancy and negatively correlated with protective factors (e.g., IDH mutation, 1p19q codel, and MGMT methylation). This evidence concerns the gene MGMT and central nervous system cancer.